MSU welcomed Dr. Noreen Henig from Kezar Life Sciences for A Closer Look: Clinical Trials and the PRESIDIO Study.
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as Dr. Noreen Henig, Chief Medical Officer, provides an overview of the clinical trial process, their importance in research and bringing new therapies to the market. Dr. Norig shares information around the PRESIDIO Study, a phase 2 clinical study currently evaluating the use of KZR-616, a selective immunoproteasome inhibitor for the treatment of polymyositis and dermatomyositis.
If you are interested in the PRESIDIO study, you can visit their website, and/or email firstname.lastname@example.org.
Noreen Roth Henig, M.D. is an accomplished leader whose career spans clinical practice, academic medicine, translational science, clinical development, medical and regulatory affairs.
Learn more about Dr. Henig by visiting https://www.kezarlifesciences.com/about/management-team